• 1
    Kornbluth A, Sachar DB. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 137185.
  • 2
    Travis SPL, Strange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn’s and Colitis 2008; 2: 2462.
  • 3
    Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005; 57: 281302.
  • 4
    Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196200.
  • 5
    Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 24: 46574.
  • 6
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 1703.
  • 7
    Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
  • 8
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 9
    Van Hees PA, Van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 3336.
  • 10
    Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 11
    Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 4217.
  • 12
    Tenjarla S, Romasanta V, Zeijdner E, et al. Release of 5-aminosalicylate from the MMXTM mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007; 24: 82640.
  • 13
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 6675.
  • 14
    Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95102.
  • 15
    Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomized trial of once- or twice-daily MMX™ mesalamine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893902.
  • 16
    Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13: 3739.
  • 17
    Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 11119.
  • 18
    Paoluzi P, D’Albasio G, Pera A, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis 2002; 34: 78793.
  • 19
    Rubin DT, Siegel CA, Kane SV, et al. Living with ulcerative colitis: differing perceptions of patients and gastroenterologists. Inflamm Bowel Dis 2008; 14: S22.
  • 20
    Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychosocial correlates of patient-physician discordance in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 217483.
  • 21
    Sewitch MJ, Abrahamowicz M, Dobkin PL, et al. Measuring differences between patients’ and physicians’ health perceptions: the patient-physician discordance scale. J Behav Med 2003; 26: 24564.
  • 22
    Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 20411.
  • 23
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 57785.
  • 24
    Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004; 39: 36573.
  • 25
    Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 48896.
  • 26
    Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005; 11: 2434.
  • 27
    Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 27286.
  • 28
    Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology 2005; 52: 50915.
  • 29
    Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 110713.
  • 30
    Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007; 15: 25763.
  • 31
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 11906.